Phase 1 dose escalation and expansion cohort study of EOS-215 as monotherapy and in combination with pembrolizumab or other anticancer treatments in participants with advanced solid tumors

Overview of Study Design

AEs, adverse events; ADA, antidrug antibody; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; ORR, overall response rate; PFS, progression-free survival; PK, pharmacokinetic; PD-1, programmed cell death protein 1; RP2D, recommended phase 2 dose; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

www.clinicaltrials.gov/study/NCT06877533

Back